Rigel Pharmaceuticals Reports Q2 2026 Financial Results with $78.7M Revenue

Rigel Pharmaceuticals, Inc. reported its financial results for the second quarter of 2026, revealing total revenues of $78.7 million, a decrease of 22.6% compared to $101.7 million in the same period last year. The decline was primarily attributed to a significant drop in contract revenues from collaborations, which fell from $42.7 million to $11.7 million year-over-year. In contrast, product sales showed an increase, with net sales rising to $67.0 million from $58.9 million, driven by higher volumes and pricing for its commercial products, particularly TAVALISSE and REZLIDHIA.

The company's net income for the quarter was $17.3 million, down from $59.6 million in the prior year, resulting in a diluted earnings per share of $0.88 compared to $3.28. Rigel's accumulated deficit decreased to approximately $997.1 million as of June 30, 2026, reflecting ongoing operational challenges and the impact of reduced collaboration revenues. The company also reported a total of 18,679,864 shares of common stock outstanding as of the end of the quarter.

In terms of strategic developments, Rigel has made significant progress in its product pipeline. The company expects to launch VEPPANU, an oral PROTAC for advanced breast cancer, in mid-August 2026, following its recent FDA approval. Additionally, Rigel has entered into a license agreement with Arvinas and Pfizer for VEPPANU, which includes a $70 million upfront payment and potential future milestone payments. The company also reported a successful transition of GAVRETO, a RET inhibitor, to its commercial portfolio, which began sales in June 2024.

Operationally, Rigel's cash and cash equivalents increased to $60.8 million from $40.6 million at the end of 2025, while short-term investments decreased significantly from $114.4 million to $34.5 million. The company has also established a revolving credit facility with MidCap Financial Trust, providing up to $40 million in borrowing capacity, which it utilized to support its operations. Rigel's management believes that its existing cash resources will be sufficient to fund operations for at least the next 12 months, although it remains cautious about potential future capital needs.

Looking ahead, Rigel anticipates that product sales will improve as it moves past seasonal reimbursement issues and continues to execute its commercial strategy. However, the company acknowledges that future revenues may be impacted by various factors, including market conditions, competition, and the success of its product launches. Rigel's ability to sustain its financial performance will depend on the successful commercialization of its products and the achievement of milestones in its collaboration agreements.